文档介绍：Big Pharma - The Way Forward
Anders Ekblom
Executive Vice President
Global Drug Development
Swedish-American Life Science Summit
20th August 2009
AstraZeneca Global R&anisation
Montreal
Boston
Wilmington
Gaithersburg
Bangalore
Osaka
Reims
Södertälje
Mölndal
Lund
Alderley Park
Charnwood
Cambridge
Shanghai
Mountain View
棒 pom板棒环氧板尼龙板尼龙棒 p://
2
Agenda
The Pharmaceutical Industry in Perspective
Challenges
Opportunities
Scorecard for Future ess – AZ Case Study
3
The Pharmaceutical Industry in Perspective
Presentation prepared for AstraZeneca: 14th May 2009
Source: IMS Health MIDAS MAT December 2008, Pharmerging markets = China, India, Russia, Brazil, Mexico, Turkey and South Korea.
Global Sales and Market Growth
Pharmaco challenges
Global Pharma Historical Market Dynamics & Current Economic Environment
The USA/top 5 Europe/Japan no longer ‘Mr Atlas’
Lower GDP growth and tax revenues will impact healthcare budgets/promote more aggressive cost containment
Biotechnology, a big growth area, affected by lack of investment funds
Several big selling drugs will face patent expires during the next few years
The most attractive areas for growth are in emerging markets
Pharmaceutical Industry - Global sales
5
$897+ million USD to bring one drug from concept to market
12 years to develop a new medicine
One in 5000 new pounds make it to market
80% drugs fail leaving 20% to fund the R&D engine
Pharmaceutical Industry - Key facts
6
This graph is based on data from panies (10 Major and 12 Mid and Other)
panies are defined as those spending ≥US$ billion in 2005 on ethical pharmaceutical R&D.
Mid and panies are defined as those spending <US$ billion in 2005 on ethical pharmaceutical R&D.
Pharmaceutical Industry - R&D expenditure
7
Pharmaceutical Industry Challenges
Industry Overview: Global R&D expenditure, development times,
global sales and NME output 1998 - 2008
*The development time data point for 2008 includes data from 2007 and 2008 o